Key result
AAV9 provided global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in mice and rats, yielding approximately 10-fold higher transgene expression (p<0.05).
Why the study?
Does AAV9 provide superior global cardiac gene transfer compared to AAV1, 6, 7, and 8 in mice and rats?
Population
Neonatal mice (4-5 days old) and adult rats (300 g, 8 weeks old)
Comparison
Adeno-associated virus serotype 9 expressing… vs AAV serotypes 1, 6, 7, and 8 expressing LacZ…
Design
Preclinical
Follow-up
up to 1 year in mice, 4 weeks in rats
Authors
Loading...
Supports AAV9 prioritization in rodent cardiac gene studies; leaves open translation to humans.
Does AAV9 provide superior global cardiac gene transfer compared to AAV1, 6, 7, and 8 in mice and rats?
p-value: p=<0.05
AAV9 provides superior, stable, and global cardiac gene transfer in rodents compared to other AAV serotypes, making it a promising vector for cardiac gene therapy.
Bish et al. (2008) studied Healthy (cardiac gene transfer model). AAV9 vs. AAV1, AAV6, AAV7, AAV8 was evaluated on Cardiac beta-galactosidase activity (transgene expression) (p=<0.05). AAV9 provided global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in mice and rats, yielding approximately 10-fold higher transgene expression (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: